New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2012
10:16 EDTINFY, DVA, RIMM, EIX, TEVA, RDS.A, QLGC, OXY, MYGN, KNXA, JNS, SJM, HMA, ELX, CNK, CF, RATEOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Bankrate (RATE) downgraded to Hold from Buy at Canaccord... Bankrate (RATE) downgraded to Sector Perform from Outperform at RBC Capital... CF Industries (CF) downgraded to Neutral from Overweight at Piper Jaffray... Cinemark (CNK) downgraded to Neutral from Overweight at JPMorgan... Emulex (ELX) downgraded to Sell from Neutral at Goldman... Health Management (HMA) downgraded to Sell from Fair Value at CRT Capital... J.M. Smucker (SJM) downgraded to Equal Weight from Overweight at Stephens... Janus Capital (JNS) downgraded to Sell from Neutral at Goldman... Kenexa (KNXA) downgraded to Market Perform from Outperform at JMP Securities... Myriad Genetics (MYGN) downgraded to Neutral from Buy at Mizuho... Occidental Petroleum (OXY) downgraded to Hold from Buy at Deutsche Bank... QLogic (QLGC) downgraded to Sell from Neutral at Goldman... Regal Entertainment (RGC) downgraded to Neutral from Overweight at JPMorgan... Royal Dutch Shell (RDS.A) downgraded to Hold from Buy at Deutsche Bank... Teva (TEVA) downgraded to Neutral from Buy at UBS... Edison International (EIX) downgraded to Market Perform from Outperform at Bernstein... Research in Motion (RIMM) downgraded to Sell from Hold at Canaccord... DreamWorks (DWA) downgraded to Sell from Hold at Stifel Nicolaus... Infosys (INFY) downgraded to Neutral from Outperform at Cowen.
News For A;TEVA;EIX;RIMM;DVA;INFY From The Last 14 Days
Check below for free stories on A;TEVA;EIX;RIMM;DVA;INFY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 24, 2014
06:45 EDTTEVATeva price target raised to $70 from $65 at Barclays
Subscribe for More Information
July 23, 2014
10:02 EDTTEVAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTTEVADeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:08 EDTTEVATeva initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 21, 2014
10:02 EDTDVAOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:11 EDTTEVAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Subscribe for More Information
08:01 EDTTEVATeva completes acquisition of Labrys
Subscribe for More Information
05:43 EDTDVADaVita downgraded to Market Perform from Outperform at Raymond James
Subscribe for More Information
July 18, 2014
16:05 EDTDVADaVita says CEO of HealthCare Partners subsidiary to step down
DaVita HealthCare Partners announced that HealthCare Partners, or HCP, president and CEO Dr. Craig Samitt is stepping down from HCP effective August 1. Kent Thiry, co-chairman and CEO of DaVita HealthCare Partners, will take over the role of CEO of HCP, working in tandem with the office of Chief Medical Officer.
11:25 EDTINFYOptions with decreasing implied volatility
Subscribe for More Information
July 17, 2014
11:12 EDTINFYOptions with decreasing implied volatility
Subscribe for More Information
07:00 EDTDVAFresenius Medical shares should be bought, says Bernstein
Bernstein notes that Fresenius' (FMS) stock has sharply underperformed versus its competitor, DaVita (DVA), since May 2012. But the firm predicts that Fresenius' core U.S. business should outperform that of DaVita going forward. Bernstein adds that it finds Fresenius' business units aside from its U.S. dialysis clinics more attractive than DaVita's businesses other than its U.S. dialysis clinics.
06:20 EDTAAgilent initiated with a Neutral at Citigroup
Target $64.
July 16, 2014
10:35 EDTINFYOptions with decreasing implied volatility
Subscribe for More Information
08:48 EDTTEVATeva says ISS supports company's nominees, shareholders' meeting proposals
Subscribe for More Information
July 15, 2014
11:13 EDTTEVAPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
10:37 EDTINFYOptions with decreasing implied volatility
Subscribe for More Information
06:28 EDTTEVAActivist shareholder says Teva to appoint new chairman, Reuters says
Subscribe for More Information
July 14, 2014
10:00 EDTINFYOptions with decreasing implied volatility: SHPG INFY CWH FDO IDIX FAST
08:04 EDTTEVATeva announces FDA acceptance of NDA filing for albuterol MDPI
Teva Pharmaceuticals Industries announced that the U.S. Food and Drug Administration has accepted for review the company’s new drug application for albuterol multi-dose dry-powder inhaler, an investigational breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease; and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older. The NDA filing includes data from eight clinical studies that evaluated the safety and efficacy of albuterol MDPI in adults and adolescents with asthma and exercise-induced bronchospasm. The NDA for albuterol MDPI has been accepted by the FDA for standard review, with a FDA Regulatory Action expected in March 2015.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use